SAN DIEGO, July 30, 2020 /PRNewswire/ -- i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, announces an up to $28.5M seed investment together with OrbiMed in four companies: Loch Lomond Therapeutics, Loch Eil Therapeutics, Loch Ness Therapeutics and Llyn Bala Therapeutics. Each of the four companies is engaged in innovative oncology discovery programs comprising breakthrough discovery-stage assets and drug targets.
In connection with the financing, Carl Gordon, Iain Dukes and Jim Sullivan, from OrbiMed, Nikolay Savchuk from Torrey Pines Investment and Prof. Ruben Abagyan from USCD have variously joined the Boards of Directors of these four companies.
Proceeds from the financing will be used to develop clinical candidates. All programs will be supported by the artificial intelligence and computer aided drug design platform of Molsoft LLC, San Diego CA and other research partners from i2020 Accelerator's global network.
About OrbiMed
OrbiMed is a leading healthcare investment firm, with over $13 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies.
About i2020 Accelerator
i2020 Accelerator strives to accelerate early stage drug discovery platforms towards advanced lead and clinical candidates within a two-year framework to rapidly de-risk novel science and enrich partner pipelines with first or best-in-class molecules. i2020's vast scientific and global resource network tailored specifically to the needs of early programs allows to accelerate development in multiple high value therapeutic areas, from immunology to inflammation and from oncology and CNS to infectious diseases and beyond. The i2020 Accelerator program inaugurated by Torrey Pines Investment in 2017 is now co-creating, growing and graduating breakthrough drug discovery programs towards future medicines. www.i2020accelerator.com
Contact: Rouslan Michtchenko, [email protected]
Advertisement
In connection with the financing, Carl Gordon, Iain Dukes and Jim Sullivan, from OrbiMed, Nikolay Savchuk from Torrey Pines Investment and Prof. Ruben Abagyan from USCD have variously joined the Boards of Directors of these four companies.
Advertisement
Proceeds from the financing will be used to develop clinical candidates. All programs will be supported by the artificial intelligence and computer aided drug design platform of Molsoft LLC, San Diego CA and other research partners from i2020 Accelerator's global network.
About OrbiMed
OrbiMed is a leading healthcare investment firm, with over $13 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies.
About i2020 Accelerator
i2020 Accelerator strives to accelerate early stage drug discovery platforms towards advanced lead and clinical candidates within a two-year framework to rapidly de-risk novel science and enrich partner pipelines with first or best-in-class molecules. i2020's vast scientific and global resource network tailored specifically to the needs of early programs allows to accelerate development in multiple high value therapeutic areas, from immunology to inflammation and from oncology and CNS to infectious diseases and beyond. The i2020 Accelerator program inaugurated by Torrey Pines Investment in 2017 is now co-creating, growing and graduating breakthrough drug discovery programs towards future medicines. www.i2020accelerator.com
Contact: Rouslan Michtchenko, [email protected]
View original content:http://www.prnewswire.com/news-releases/i2020-accelerator-of-torrey-pines-investment-in-breakthrough-cancer-programs-together-with-orbimed-301102813.html
SOURCE i2020 Accelerator
